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ABSTRACT
Guillain-Barré Syndrome (GBS) is a neurologic disease that causes ascending paralysis and is triggered by 
a preceding bacterial or viral infection. Several studies have shown that patients with GBS have a recent 
history of infection due to Campylobacter jejuni. A literature review of published studies that reported rates 
of Campylobacter infection before or in conjunction with GBS was done. These reported data were used for 
calculating the proportion of GBS cases who tested positive for Campylobacter compared to the control pop-
ulation and the incidence of GBS among patients infected with Campylobacter. Results of the analysis sug-
gest that 31% of 2,502 GBS cases included in these papers are attributable to Campylobacter infection.
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INTRODUCTION
Since the near global eradication of poliomye- 
litis, Guillain-Barré Syndrome (GBS) has become 
the most common cause of acute neuromuscular 
paralysis (1). GBS is an acute neurologic disease 
driven by autoimmunity and molecular mimicry 
in which the body stages a cell-mediated and hu-
moral immunological response against peripheral 
nerve myelin (2). Asbury and Cornblath clinically 
defined GBS as a progressive motor weakness of 
more than one limb with low or absent reflexes 
and no other identifiable cause (3). The global in-
cidence of GBS ranges from 0.4 to 4.0 (median 1.3) 
cases per 100,000 people annually, occurring slight-
ly more often in adolescents and young adults than 
in children (2,3). In its acute phase, GBS can cause 
severe disability and even death (4). A recent sys-
tematic review of GBS estimated that 40-70% of all 
GBS cases are preceded by an acute infectious ill-
ness, of which 22-53% are upper respiratory infec-
tions and 6-26% are gastrointestinal infections, one 
of the most common being enteritis due to Campy-
lobacter (5,6). 
GBS  can  be  classified  into  demyelinating  and  axo- 
nal subtypes. The demyelinating subtype—acute 
inflammatory demyelinating polyneuropathy 
(AIDP)—is characterized by demyelination of neu-
rons whereas demyelination is absent in the ax-
onal subtypes—acute motor axonal neuropathy 
(AMAN) and acute motor sensory axonal neuropa-
thy (AMSAN) (7). AIDP is common in North Amer-
ica and Europe while AMAN/AMSAN have been 
more commonly found in studies in China, Japan, 
and Mexico (2,8,9). Although both the subtypes 
have been associated with infection due to Campy-
lobacter, it is has been shown that Campylobacter is 
more widely associated with AMAN (10-12). 
Campylobacter jejuni was first associated with GBS in 
1982 when Rhodes and Tattersfield reported a case 
of GBS following enteric infection with C. jejuni 
(13,14). It is difficult to positively associate C. jejuni 
with GBS because the bacteria are usually elimi-
nated from the body within 16 days of infection 
and before the onset of neurological symptoms, 
which normally begin 10 days to 3 weeks after the 
onset of diarrhoea (1,2). Although Campylobacter is 
prevalent in most parts of the world, it is not yet 
routinely diagnosed in rural health clinics. For this 
reason, many Campylobacter-associated GBS cases 
may go unrecognized because by the time the per-
son presents with GBS, Campylobacter is no longer 
present (15,16). Poropatich KO et al. Campylobacter-associated Guillain-Barré Syndrome
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Results of a previous overview of literature sug-
gested that Campylobacter infection is responsi-
ble for 13-72% of GBS cases; however, this review 
was not designed to systematically review the 
literature (2). Thus, we did a systematic review of 
published studies to estimate the proportion of 
GBS cases that may be attributed to Campylobacter 
among persons of all ages and from all regions of 
the world.  
MATERIALS AND METHODS
We performed a PubMed search of studies published 
from July 1982 to 28 June 2010 that investigated 
the relationship between infection due to Campylo-
bacter and GBS. We searched using combinations of 
the following Medical Subjects Headings (MeSH): 
‘Guillain-Barré Syndrome’ and ‘campylobacter’ and 
the key words: ‘guillain barré syndrome’, ‘GBS’, 
‘acute autoimmune neuropathy’, ‘acute inflamma-
tory polyneuropathy’, ‘acute inflammatory demy-
elinating polyneuropathy’, ‘AIDP’, ‘AMAN’, and 
‘campylobacter’. We also searched the reference 
lists of retrieved manuscripts to identify additional 
studies. 
We included cohort studies of persons with labo- 
ratory-confirmed infection due to Campylobacter 
who were followed prospectively to assess subse-
quent GBS cases and retrospective case-control stud-
ies that tested for Campylobacter infections among 
GBS-confirmed cases and non-GBS controls. We 
excluded case-control studies with fewer than 15 
GBS cases and cohort studies, including cases of 
GBS that developed more than six months after 
a confirmed infection due to Campylobacter. Stud-
ies were included if serum and stool samples were 
collected during the acute phase of GBS—within 
24-48 hours of patient’s admission to hospital and 
no longer than four weeks after admission. Stud-
ies were excluded if they relied on a complement 
fixation assay (CFA) for the diagnosis of Campylo-
bacter. 
For case-control studies, the primary outcome con-
sidered was laboratory-confirmed presence of infec-
tion due to C. jejuni in GBS cases and controls. For 
cohort studies, the primary outcome considered 
was the development of GBS in persons with labo-
ratory-confirmed infection due to Campylobacter. 
Clinical features of GBS were analyzed, and ante-
cedent infections were investigated. Definitions of 
GBS in the studies were based on currently-accepted 
criteria for diagnosing GBS (i.e. a progressive, sym-
metric ascending paralysis with a relative sensory 
sparing in more than one extremity with hypo- or 
areflexia) (3,17). Studies were excluded from review 
if these did not explicitly state or cite their crite-
ria for diagnosis of GBS. Studies were included if 
these used appropriate microbiological methods 
(serological assays and stool cultures) for detecting 
Campylobacter species (13). 
We reviewed all titles and abstracts to identify eli-
gible studies. Full manuscripts were obtained for 
potentially eligible studies. 
Statistical methods
For case-control studies, we calculated the median 
and interquartile range (IQR) for cases and controls 
and Campylobacter-positive cases and controls. The 
Microsoft Excel software was used for calculating 
medians and IQR (18). 
RESULTS
We screened 573 potential studies (Fig.) for inclu-
sion in the review. After applying the inclusion and 
exclusion criteria, we included two prospective co-
hort studies (16,19) and 30 case-control studies (Ta-
ble). In total, case-control studies yielded 2,502 GBS 
subjects and 3,419 controls. One study took place 
in the UN-classified (20) least-developed countries 
(21)—11 in developing countries (10,11,22-30) and 
20 in developed countries (12,16,19,31-47). 
For case-control studies, rates of Campylobacter in-
fection varied among the GBS patients and controls 
from 4.8% to 71.7% and 0% to 28.1% respectively. 
The median positivity for Campylobacter among the 
GBS cases was 35.4% (IQR 28.3-44.9), and among 
the controls, it was 4.4% (IQR 1.2-8.8), suggesting 
that 31.0% of the GBS cases may be attributable to 
a previous infection due to Campylobacter.  
We identified two cohort studies meeting our in-
clusion criteria (16,19). In the study by McCarthy 
et al., 0.03% of Campylobacter cases (n=29,563) de-
veloped GBS, which can be expressed as 30.4 cases 
of GBS per 100,000 cases of C. jejuni-associated 
infection [95% confidence interval (CI) 13.9-57.8] 
(16). In a population-based cohort study, Tam et al. 
found that, of 2,560 persons infected with Campy-
lobacter who received subsequent medical follow-
up, three cases of GBS were found, yielding an in-
cidence of 117 per 100,000 cases of C. jejuni (95% 
CI 0.38-3.63) (19).  
DISCUSSION
In this review, we found 32 studies that met our 
inclusion/exclusion criteria and measured the asso-
ciation of infection due to Campylobacter with GBS. 
One of the challenges in determining the incidence 
of Campylobacter-associated GBS is that many cases 
of Campylobacter go unreported. For this reason, 
most studies focus on a sample of persons already Poropatich KO et al.
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Excluded (n=27)
All case-control studies with
<15 GBS cases (n=3), case-
control studies without
Campylobacter data (n=20),
Does not provide criteria
GBS diagnosis (n=4)
Articles retrieved and read for
more detailed evaluation
n=99
Case-control and study cohort
studies included in ﬁrst draft
n=72
Excluded (n=40)
Retrospective studies with out
control group (n=27), studies
in foreign language other than
Spanish/French (n=7), no
deﬁnition for Campylobacter
positive (n=2), combined GBS
and Miller Fisher Syndrome
data (n=1), unreliable laboratory
assay (n=2), combined results
from two lablaboratories (n=1)
Case-control and study cohort
studies included in ﬁnal
review
n=32
Abstracts of potential studies
identiﬁed by PubMed search
n=573
Excluded (n=474)
Did not provide
Campylobacter-GBS data
(n= 212), not a cohort/case-
control study (n=262)
Case-control
n=30
Cohort
n=2
Fig. Results of literature review
diagnosed with GBS and perform retrospective 
analyses to determine if they were infected with C. 
jejuni (2). Large cohort studies are ideal for deter-
mining the actual incidence of Campylobacter-asso- 
ciated GBS because they identify Campylobacter 
cases at the time of active infection and are, thus, 
less likely to miss a Campylobacter infection because 
of poor timing. Unfortunately, these studies are rare. 
We used a standard definition for GBS to minimize 
differences in diagnostic criteria among studies (3). 
These are the internationally-accepted criteria cur-
rently used for diagnosing GBS and helped control 
for study heterogeneity.
One limitation of this analysis is controlling for 
heterogeneity among studies that met our inclu-
sion criteria. Depending on whether studies used 
serologic assays or stool samples for the diagnosis 
of Campylobacter, different positive values could be 
shown. Serology is the preferred mechanism of de-
tection because Campylobacter-specific antibodies 
can be detected in serum of the patient for an in-
definite length of time compared to Campylobacter 
antigens in stool samples, which are cleared, on av-
erage, 16 days after infection. Thus, there could be 
many false-negative stool cultures in GBS patients 
in studies that rely solely on stool culture for the di-
agnosis of Campylobacter (48). Additionally, there is 
no serological test that is specific for Campylobacter 
infection as far back as in the two months before 
the onset of GBS; so, there is potential misclassifica-
tion of exposure in retrospective serological studies, 
which comprise the bulk of the case-control studies 
considered in this analysis. 
Variations in serological assays could also affect 
results of study; antigens used and endpoints for 
positivity often vary with different assays (48). It is 
preferable that studies using serology to adhere to 
strict criteria for recent diagnosis of Campylobacter Poropatich KO et al. Campylobacter-associated Guillain-Barré Syndrome
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(i.e. positive ELISA for at least 2 classes of antibod-
ies) to avoid false-positive results. However, we did 
not specifically exclude studies on the basis of the 
number of Campylobacter-specific antibodies they 
used, only if they did not explicitly state what their 
standard was for seropositivity of Campylobacter. 
Finally, we did not control for improving technolo-
gies for the detection of Campylobacter over the 
years of the studies, which could also confound the 
comparison of results from older studies with more 
recent studies. 
Another limitation to take into consideration is the 
overestimation of Campylobacter infectivity in con-
trol groups. While serological evidence of Campylo-
bacter infection is likely indicative of recent infec-
tion in GBS cases due to the strong temporal link 
between Campylobacter infection and GBS, this is 
not the case for controls. If controls test positive, 
there is no way of knowing how long ago their 
infection occurred because antibody titres remain 
elevated for an extended period. The median value 
of 4.4% for Campylobacter positivity in the con-
trol group in our study may represent individu-
als with infection due to Campylobacter beyond 
two months and, thus, could be an overestimate 
of active Campylobacter infections in the general 
population. If this were the case, the prevalence of 
Campylobacter  -associated infections would actually 
be greater between cases and controls. 
The instance of heterogeneous control popula-
tions in the studies is an additional limitation of 
this analysis. Some studies included controls with 
other neurological disorders with preceding C. je-
juni-associated infection as high as 28.1%, which 
is considerably higher than that has been observed 
in other control groups. Selection of controls in the 
study could alter the difference in Campylobacter 
positivity between GBS cases and controls, depend-
ing on whether the control groups’ risk of expo-
sure was the same as the GBS group or different. 
For instance, household controls could have a risk 
comparable to GBS cases, and high rates of seropo- 
sitivity among these controls could reflect trans-
mission of Campylobacter from cases and controls, 
along with unhygienic living conditions in devel-
oping countries. 
We were also unable to search the Chinese medical 
literature databases or review Chinese language pa-
pers identified in PubMed. We recognize that these 
data may exist and would better help us under-
stand the associations of GBS with Campylobacter 
in China. 
While infection due to Campylobacter is not nor-
mally associated with high rates of mortality in 
developed countries, 4-15% of patients with GBS 
may die within the first year after onset (49). C. 
jejuni has been identified as a potential predictor 
of poor outcome in persons suffering from GBS 
for inducing a more severe autoimmune response 
and greater axonal damage (2). Some studies re-
port that preceding Campylobacter infection can 
increase the severity of GBS in patients, i.e. death, 
mechanical ventilation, etc. (2). This is problematic 
in poorer countries that usually have increased fre-
quencies of infection due to Campylobacter because 
persons who develop GBS may have limited access 
to healthcare and treatment required for GBS. For 
these reasons, the appropriate measures must be 
taken to reduce the incidence of Campylobacter-
associated GBS. This can be achieved through 
reducing the frequency of Campylobacter cases by 
improving sanitation, preventing the faecal-oral 
routes of transmission of Campylobacter.   
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